Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

Rasmus Svane Ditlev Severinsen, Marie Beck Enemark, Julie Bondgaard Mortensen, Eigil Kjeldsen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Gorm von Oettingen, Holger Jon Møller, Christopher Vejgaard, Mette Bjerre, Francesco d'Amore

Blood (2021) 138 (Supplement 1): 1334.

https://doi.org/10.1182/blood-2021-144882

Published: 2021

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Francesco d'Amore, Judit Joergensen, Ida Blok Sillesen, Erik Segel, Hans Bentzen, Michael Thorsgaard, Elisa Jacobsen Pulczynski, Bjarne Bach Pedersen, Dorte Gillström, Michael Clausen, Peter Kamper, Trine Silkjaer, Lars C. Gormsen, Sirpa Leppä, Helle Toldbod

Blood (2014) 124 (21): 5435.

https://doi.org/10.1182/blood.V124.21.5435.5435

Published: 2014

Journal Articles

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Elisa Jacobsen Pulczynski, Peter Kamper, Unn-Merete Fagerli, Martin Erlanson, Outi Kuittinen, Alexander Fosså, Bjørn Østenstad, Oystein Fluge, Martin Maisenhølder, Hans Hagberg, Mikael Eriksson, Marie Nordstrøm, Sirpa Leppa

Blood (2011) 118 (21): 1602.

https://doi.org/10.1182/blood.V118.21.1602.1602

Published: 2011

Journal Articles

Malignant Lymphoma and Breast Implants: a Case of Diffuse Large B-Cell Lymphoma (DLBCL) with Implant-near Relapse Localization

Maja Ølholm Vase, MD, Elisa Jacobsen Pulczynski, MD, Knud Bendix, MD, d'Amore Francesco

Blood (2010) 116 (21): 5103.

https://doi.org/10.1182/blood.V116.21.5103.5103

Published: 2010

NARROW

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Malignant Lymphoma and Breast Implants: a Case of Diffuse Large B-Cell Lymphoma (DLBCL) with Implant-near Relapse Localization

Email alerts

ASH Publications

American Society of Hematology

Patients with Primary Central Nervous System Lymphoma Have High Levels of Soluble Programmed Cell Death Protein 1 in Their Pretherapeutic Cerebrospinal Fluid

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Preliminary Clinical Experience on the Efficacy and Feasibility of a New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

Age-Adjusted Combined Immunochemotherapy without Radiotherapy in Newly Diagnosed PCNSL – A Phase II Trial of the Nordic Lymphoma Group

Malignant Lymphoma and Breast Implants: a Case of Diffuse Large B-Cell Lymphoma (DLBCL) with Implant-near Relapse Localization

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only